IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Betz, et al.

Patent No: 6,984,492) Int. Cl: C12Q 1/68

Issued: January 10, 2006) U.S. Cl.: 435/6

For: METHODS AND COMPOSITIONS FOR TREATING HERPES

INFECTIONS

RECONSIDERATION REQUEST FOR CERTIFICATE OF CORRECTION

DECISIONS & CERTIFICATES OF CORRECTION BRANCH

Attn: Stacy Powell, Sr. Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Applicants of the above-identified patent hereby request that a Certificate of Correction be issued for this U.S. Patent.

The following reference was omitted from the U.S. Patent Documents (Item 56): U.S. Pat. No. 6,307,028 B1, 10/2001, Lebing, *et al.*, 530/390.1. Applicants contend the submission of this document was properly made in compliance with 37 CFR 1.97 and 1.98.

Applicants believe that the submission of the enclosed document, Form PTO-1449, submitted January 8, 2004, and subsequently initialed by the Examiner, supports the claim that the Patent Office is in error.

Respectfully submitted,

Carl B. Massey, Jr. Reg. No. 44,224

Attorney for Assignee

Date: An 1, 2006

Womble Carlyle Sandridge & Rice, PLLC

P.O. Box 7037

Atlanta, Georgia 30357-0037

Telephone: (336) 721-3681 / Facsimile: (336) 726-8074

Docket: B185 1230.1

ORM 18 0 1449			U.S. DEPARTMENT OF COMMERCE				ATTY DKT NO.			SERIAL NO.		
O A TO SO	اهُ	PATENT AND	PATENT AND TRADEMARK OFFICE				B185 1230.1			10/656,781		
IAN 0 8 2004	5	•				APPLICANT						
JAN 5 5 225) n	NIEODALA TION	DICCI OC	ar i de la comp		Ulrich Betz, et al. FILING DATE GROUP						
INFORMATION DISCLOSURE STATEMENT BY APPLICANT						09/05/0			GRO 1614			
& TRADEMARK		TAILMENIB	Y APPLIC	CANT			1014					
			U.S.	PATENT DOC	UMENTS	Š						
EXAMINER		DOCUMENT			NAME		CL.	SU	SUBCL.		NG DATE	
INITIAL	 	NO.		<u> </u>							PPROP.	
PI		U.S. Pat. No. 6,307,028 B1	10/23/01	Lebing, et al.			530	390	390.1			
								+-				
			FOREI	GN PATENT DO	OCUMEN	NTS						
		DOCUMENT N	DOCUMENT NO. DAT				CL.	SUB			TRANSLATION	
								 		YES	NO	
							ļ <u>.</u>	 	$-\!\!+$			
	 			-			 	├	 -		 	
	 							 				
								 	-			
								 	$\neg \top$		·	
		OTHER DO	CUMENTS ((Incl. Author, Ti	tle, Date,	Pertinent	t pages, et	e.)				
41	DI	Elrich, K.S., et a	OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) Elrich, K.S., et al., "Prevention and Treatment of Experimental Herpes Simplex Virus Encephalitis with									
7)		Human Immune	Human Immune Serum Globulin," Antimicrobial Agents and Chemotherapy, 31(7): 1006-1009 (1987).									
	D2	Epstein, S.P, et al., "Efficacy of Polyclonal Antibodies for Treatment of Ocular Herpes Simplex In Cornea, 20(5): 495-500 (2001).								•		
	D3	LeBlanc, R.A., e	LeBlanc, R.A., et al., "Treatment of HSV-1 Infection with Immunoglobulin or Acyclovir: Comparison of									
		Their Effects on	Their Effects on Viral Spread, Latency, and Reactivation," Virology, 262(1): 230-236 (1999).									
	D4	Raizman, M.B, a	Raizman, M.B, and C.S. Foster, "Passive transfer of anti-HSV-1 IgG protects against stromal keratitis in									
- 	D5	Ditable M.H. of	mice," Current Eye Research, 7(8): 823-829 (1988).									
	D5 Ritchie, M.H., et al., "Passive Transfer of Anti-Herpes Simplex Virus Type 2 Monoclonal and Polyclonal Antibodies Protect Against Herpes Simplex Virus Type 1-Induced but Not Herpes Simplex Virus Type 2-											
Induced Stromal Keratitis," Investigative Opthalmology & Visual Science, 34(8): 2460-2468									68 (1993) ype 2-		
								<u>\-/-</u>	<u> </u>	00 (2222)·	
ļ												
 '												
EXAMINER	L				DATE	CONSID	ERED		 -			
Did Million		<u> </u>			DAIL	COMOID	EKED	61	/ Z,	105		
EXAMINER:	Initial if	f citation considered,	whether or n	ot citation is in co	onformanc	e with MI	 PEP 609: c	traw lir	ne thro	woh citat	ion if not	
in conformanc	e and no	ot considered. Includ	le copy of this	s form with next c	ommunic	ation to a	pplicant.		10 11	W B 	ion ii iio.	